Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408705 | 1.00 | PARP1 (0.92) | PARP1LMNA | |
| SCHEMBL3388183 | 0.96 | PARP1 (1.00) | PARP1 | |
| SCHEMBL3385144 | 0.91 | PARP1 (0.80) | PARP1LMNA | |
| SCHEMBL3388610 | 0.89 | PARP1 (1.00) | PARP1 | |
| SCHEMBL3385663 | 0.87 | PARP1 (0.77) | PARP1LMNA | |
| SCHEMBL13007107 | 0.86 | PARP1 (0.70) | PARP1LMNA | |
| SCHEMBL30132754 | 0.86 | PARP1 (0.73) | PARP1LMNA | |
| SCHEMBL25890317 | 0.86 | PARP1 (0.73) | PARP1LMNA | |
| SCHEMBL4440678 | 0.86 | PARP1 (0.79) | PARP1 | |
| SCHEMBL13007009 | 0.86 | PARP1 (0.72) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-12 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20170319543-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2305221-B1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARM LTD (GB) | 2015-05-20 | — | — | EP | disclosed |
| US-8143241-B2 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-03-27 | — | — | US | disclosed |
| EP-2305221-A1 | Dna damage repair inhibitors for treatment of cancer | Kudos Pharmaceuticals Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| EP-1501822-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319543-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | PARP2, MRE11, PARP1 | PARP1 3/4885LMNA 1800/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | PARP1 1298/4885LMNA 2164/4885 |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | PARP1 3/4885LMNA 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.